Comparative Pharmacology
Head-to-head clinical analysis: APOGEN versus CIDOFOVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APOGEN versus CIDOFOVIR.
APOGEN vs CIDOFOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apocynin is a prodrug that is activated by peroxidases to form dimers that inhibit NADPH oxidase (NOX) enzyme complexes, reducing superoxide production. It also exhibits antioxidant and anti-inflammatory properties.
Cidofovir is a nucleotide analog that inhibits viral DNA polymerase by competing with deoxycytidine triphosphate for incorporation into viral DNA, resulting in chain termination and inhibition of viral replication.
10 mg orally once daily, with or without food.
5 mg/kg intravenously once weekly for 2 weeks, then 5 mg/kg every 2 weeks. Administer with probenecid 2 g orally 3 hours before dose, then 1 g at 2 and 8 hours after dose. Hydrate with 1 L normal saline before infusion.
None Documented
None Documented
Clinical Note
moderateCidofovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cidofovir."
Clinical Note
moderateTenofovir disoproxil + Cidofovir
"Tenofovir disoproxil may decrease the excretion rate of Cidofovir which could result in a higher serum level."
Terminal half-life 3.5 hours; dose adjustment required in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 2.5 hours. However, the intracellular half-life of the active diphosphate metabolite is >48 hours, supporting once-weekly dosing.
Renal: 90% unchanged; fecal: 10% as metabolites.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for approximately 90% of the administered dose. Biliary/fecal elimination is minimal (<5%).
Category C
Category D/X
Antiviral
Antiviral